Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F14%3A10281583" target="_blank" >RIV/00216208:11160/14:10281583 - isvavai.cz</a>

Result on the web

<a href="http://www.degruyter.com/view/j/acph.2014.64.issue-2/acph-2014-0018/acph-2014-0018.xml" target="_blank" >http://www.degruyter.com/view/j/acph.2014.64.issue-2/acph-2014-0018/acph-2014-0018.xml</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2478/acph-2014-0018" target="_blank" >10.2478/acph-2014-0018</a>

Result language

angličtina

Original language name

Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro

Original language description

Catechins may influence both desirable and undesirable effects of many drugs. In this study, the in vitro effect of (+)-catechin, (-)-epicatechin, (-)-epigallocatechin, (-)-epicatechin gallate, and (-)-epigallocatechin gallate (EGCG) on the efficacy of anticancer drug doxorubicin (DOX) was studied in HCT-8 cancer cells. Rat hepatocytes were used to study the influence of EGCG on DOX hepatotoxicity. Cell proliferation and viability were studied by 3-[4,5-dimethylthiazol- 2-yl]-2,5-diphenyl tetrazolium bromide and neutral red uptake test assays. Formation of reactive oxygen species (ROS) was determined using the dichlorofluorescein assay. All of the studied catechins (1-25 mu mol L-1) had no effect on the proliferation of intestinal cancer cells and didnot affect the antiproliferative effect of DOX (1-8 mu mol L-1) in these cells. Moreover, EGCG at 25 mu mol L-1 increased the viability of isolated hepatocytes and significantly protected these cells against DOX-induced toxicity and ROS p

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FR - Pharmacology and apothecary chemistry

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Acta Pharmaceutica

ISSN

1330-0075

e-ISSN

—

Volume of the periodical

64

Issue of the periodical within the volume

2

Country of publishing house

CR - COSTA RICA

Number of pages

11

Pages from-to

199-209

UT code for WoS article

000337705100005

EID of the result in the Scopus database

—